Symptomatic Intracerebral Hemorrhage in Acute Ischemic Stroke After Thrombolysis With Intravenous Recombinant Tissue Plasminogen Activator
- 1 September 2014
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 71 (9), 1181-1185
- https://doi.org/10.1001/jamaneurol.2014.1210
Abstract
Importance Intravenous thrombolysis remains the mainstay treatment for acute ischemic stroke. One of the most feared complications of the treatment is thrombolysis-related symptomatic intracerebral hemorrhage (sICH), which occurs in nearly 6% of patients and carries close to 50% mortality. The treatment options for sICH are based on small case series and expert opinion, and the efficacy of recommended treatments is not well known. Objective To provide an overview on the rationale and mechanism of action of potential treatments for sICH that may reverse the coagulopathy before hematoma expansion occurs. Evidence Review Evidence-based peer-reviewed articles, including randomized trials, case series and reports, and retrospective reviews, were identified in a PubMed search on the mechanism of action of intravenous recombinant tissue plasminogen activator and the rationale of various potential treatments using the coagulation cascade as a model. The search encompassed articles published from January 1, 1990, through February 28, 2014. Findings The current treatments may not be sufficient to reverse coagulopathy early enough to prevent hematoma expansion and improve the outcome of thrombolysis-related hemorrhage. Conclusions and Relevance Given the mechanism of action of intravenous recombinant tissue plasminogen activator, clinical studies could include agents with a fast onset of action, such as prothrombin complex concentrate, recombinant factor VIIa, and ε-aminocaproic acid, as potential therapeutic options.This publication has 28 references indexed in Scilit:
- Guidelines for the Early Management of Patients With Acute Ischemic StrokeStroke, 2013
- Risk Score for Intracranial Hemorrhage in Patients With Acute Ischemic Stroke Treated With Intravenous Tissue-Type Plasminogen ActivatorStroke, 2012
- Improved Prediction of Poor Outcome After Thrombolysis Using Conservative Definitions of Symptomatic HemorrhageStroke, 2012
- Guidelines for the Management of Spontaneous Intracerebral HemorrhageStroke, 2010
- Management of Thrombolysis-Associated Symptomatic Intracerebral HemorrhageArchives of Neurology, 2010
- Fibrinogen Levels Following Amicar in Surgery for Idiopathic ScoliosisSpine, 2007
- Recombinant Factor VIIa for Rapid Reversal of Warfarin Anticoagulation in Acute Intracranial HemorrhageMayo Clinic Proceedings, 2004
- Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)–Induced Hemorrhage After Thromboembolic StrokeStroke, 2000
- Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: Experience from the GUSTO-I TrialAmerican Heart Journal, 1999
- Tissue Plasminogen Activator for Acute Ischemic StrokeThe New England Journal of Medicine, 1995